Brooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
Key highlights
- Reported standalone net profit after tax of ₹69.99 crore and consolidated net profit of ₹65.82 crore for H1 ended September 30, 2026
- Partially divested 11.48% stake in Brooks Steriscience Limited for ₹74.74 crore, recognizing exceptional gain of ₹74.70 crore
- Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY2027 on November 7, 2026
Original filing
Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Brooks Laboratories
- Financial resultsBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Acquisition / mergerNotableBrooks Laboratories Limited approves scheme to demerge manufacturing business
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
- Kilitch Drugs (India) approves unaudited Q2 and half-year results to 30 Sept 2026
- Mangalam Seeds approves Q2 results, divests subsidiary and associate stakes
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.